Hypomyelinating leukodystrophies in adults: Clinical and genetic features.

genetic leukoencephalopathies hypomyelination leukodystrophies peroxisome biogenesis disorders spastic paraplegias

Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
03 2021
Historique:
received: 21 07 2020
revised: 07 11 2020
accepted: 10 11 2020
pubmed: 16 11 2020
medline: 13 8 2021
entrez: 15 11 2020
Statut: ppublish

Résumé

Little is known about hypomyelinating leukodystrophies (HLDs) in adults. The aim of this study was to investigate HLD occurrence, clinical features, and etiology among undefined leukoencephalopathies in adulthood. We recruited the patients with cerebral hypomyelinating magnetic resonance imaging pattern (mild T2 hyperintensity with normal or near-normal T1 signal) from our cohort of 62 adult index cases with undefined leukoencephalopathies, reviewed their clinical features, and used a leukoencephalopathy-targeted next generation sequencing panel. We identified 25/62 patients (~40%) with hypomyelination. Cardinal manifestations were spastic gait and varying degree of cognitive impairment. Etiology was determined in 44% (definite, 10/25; likely, 1/25). Specifically, we found pathogenic variants in the POLR3A (n = 2), POLR1C (n = 1), RARS1 (n = 1), and TUBB4A (n = 1) genes, which are typically associated with severe early-onset HLDs, and in the GJA1 gene (n = 1), which is associated with oculodentodigital dysplasia. Duplication of a large chromosome X region encompassing PLP1 and a pathogenic GJC2 variant were found in two patients, both females, with early-onset HLDs persisting into adulthood. Finally, we found likely pathogenic variants in PEX3 (n = 1) and PEX13 (n = 1) and potentially relevant variants of unknown significance in TBCD (n = 1), which are genes associated with severe, early-onset diseases with central hypomyelination/dysmyelination. A hypomyelinating pattern characterizes a relevant number of undefined leukoencephalopathies in adulthood. A comprehensive genetic screening allows definite diagnosis in about half of patients, and demonstrates the involvement of many disease-causing genes, including genes associated with severe early-onset HLDs, and genes causing peroxisome biogenesis disorders.

Sections du résumé

BACKGROUND AND PURPOSE
Little is known about hypomyelinating leukodystrophies (HLDs) in adults. The aim of this study was to investigate HLD occurrence, clinical features, and etiology among undefined leukoencephalopathies in adulthood.
METHODS
We recruited the patients with cerebral hypomyelinating magnetic resonance imaging pattern (mild T2 hyperintensity with normal or near-normal T1 signal) from our cohort of 62 adult index cases with undefined leukoencephalopathies, reviewed their clinical features, and used a leukoencephalopathy-targeted next generation sequencing panel.
RESULTS
We identified 25/62 patients (~40%) with hypomyelination. Cardinal manifestations were spastic gait and varying degree of cognitive impairment. Etiology was determined in 44% (definite, 10/25; likely, 1/25). Specifically, we found pathogenic variants in the POLR3A (n = 2), POLR1C (n = 1), RARS1 (n = 1), and TUBB4A (n = 1) genes, which are typically associated with severe early-onset HLDs, and in the GJA1 gene (n = 1), which is associated with oculodentodigital dysplasia. Duplication of a large chromosome X region encompassing PLP1 and a pathogenic GJC2 variant were found in two patients, both females, with early-onset HLDs persisting into adulthood. Finally, we found likely pathogenic variants in PEX3 (n = 1) and PEX13 (n = 1) and potentially relevant variants of unknown significance in TBCD (n = 1), which are genes associated with severe, early-onset diseases with central hypomyelination/dysmyelination.
CONCLUSIONS
A hypomyelinating pattern characterizes a relevant number of undefined leukoencephalopathies in adulthood. A comprehensive genetic screening allows definite diagnosis in about half of patients, and demonstrates the involvement of many disease-causing genes, including genes associated with severe early-onset HLDs, and genes causing peroxisome biogenesis disorders.

Identifiants

pubmed: 33190326
doi: 10.1111/ene.14646
doi:

Substances chimiques

Microtubule-Associated Proteins 0
TBCD protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

934-944

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 European Academy of Neurology.

Références

van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134(3):351-382. https://doi.org/10.1007/s00401-017-1739-1
van der Knaap MS, Schiffmann R, Mochel F, Wolf NI. Diagnosis, prognosis, and treatment of leukodystrophies. Lancet Neurol. 2019;18(10):962-972. https://doi.org/10.1016/S1474-4422(19)30143-7
Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72(8):750-759. https://doi.org/10.1212/01.wnl.0000343049.00540.c8
Lynch DS, Wade C, Paiva ARBd, et al. Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. J Neurol Neurosurg Psychiatry. 2019;90(5):543-554. https://doi.org/10.1136/jnnp-2018-319481
Barkovich AJ, Kjos BO, Jackson DE, Norman D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology. 1988;166(1 Pt 1):173-180. https://doi.org/10.1148/radiology.166.1.3336675
Salsano E. Leukodystrophy or genetic leukoencephalopathy? Nature does not make leaps. Mol Genet Metab. 2015;114(4):491-493. https://doi.org/10.1016/j.ymgme.2015.02.005
Ahmed RM, Murphy E, Davagnanam I, et al. A practical approach to diagnosing adult onset leukodystrophies. J Neurol Neurosurg Psychiatry. 2014;85(7):770-781. https://doi.org/10.1136/jnnp-2013-305888
Parikh S, Bernard G, Leventer RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015;114(4):501-515. https://doi.org/10.1016/j.ymgme.2014.12.434
Pouwels PJW, Vanderver A, Bernard G, et al. Hypomyelinating leukodystrophies: translational research progress and prospects. Ann Neurol. 2014;76(1):5-19. https://doi.org/10.1002/ana.24194
Osterman B, Piana RL, Bernard G. Advances in the diagnosis of leukodystrophies. Future Neurology. 2012;7(5):595-612.
Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics. 2005;6(1):1-16. https://doi.org/10.1007/s10048-004-0207-y
Orthmann-Murphy JL, Salsano E, Abrams CK, et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain. 2009;132(Pt 2):426-438. https://doi.org/10.1093/brain/awn328
Sagnelli A, Magri S, Farina L, et al. Early-onset progressive spastic paraplegia caused by a novel TUBB4A mutation: brain MRI and FDG-PET findings. J Neurol. 2016;263(3):591-593. https://doi.org/10.1007/s00415-016-8020-8
Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain. 2017;140(5):1204-1211. https://doi.org/10.1093/brain/awx045
Sartori G, Colombo L, Vallar G, Rusconi M, Pinarello A. TIB: Test di Intelligenza Breve per la valutazione del quoziente intellettivo attuale e pre-morboso. La Professione di Psicologo. 1997;1:2-24.
Bernard G, Chouery E, Putorti M, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet. 2011;89(3):415-423. https://doi.org/10.1016/j.ajhg.2011.07.014
Mendes MI, Green LMC, Bertini E, et al. RARS1-related hypomyelinating leukodystrophy: expanding the spectrum. Ann Clin Transl Neurol. 2020;7(1):83-93. https://doi.org/10.1002/acn3.50960
Wolf NI, Salomons GS, Rodenburg RJ, et al. Mutations in RARS cause hypomyelination. Ann Neurol. 2014;76(1):134-139. https://doi.org/10.1002/ana.24167
Flex E, Niceta M, Cecchetti S, et al. Biallelic mutations in TBCD, encoding the tubulin folding cofactor D, perturb microtubule dynamics and cause early-onset encephalopathy. Am J Hum Genet. 2016;99(4):962-973. https://doi.org/10.1016/j.ajhg.2016.08.003
Kunii M, Doi H, Ishii Y, et al. Genetic analysis of adult leukoencephalopathy patients using a custom-designed gene panel. Clin Genet. 2018;94(2):232-238. https://doi.org/10.1111/cge.13371
Siow S-F, Cameron Smail R, Ng K, Kumar KR, Sue CM. Motor evoked potentials in hereditary spastic paraplegia-a systematic review. Front Neurol. 2019;10:967. https://doi.org/10.3389/fneur.2019.00967
Abrams CK, Scherer SS, Flores-Obando R, et al. A new mutation in GJC2 associated with subclinical leukodystrophy. J Neurol. 2014;261(10):1929-1938. https://doi.org/10.1007/s00415-014-7429-1
Kancheva D, Chamova T, Guergueltcheva V, et al. Mosaic dominant TUBB4A mutation in an inbred family with complicated hereditary spastic paraplegia. Mov Disord. 2015;30(6):854-858. https://doi.org/10.1002/mds.26196
Harting I, Karch S, Moog U, Seitz A, Pouwels PJW, Wolf NI. Oculodentodigital dysplasia: a hypomyelinating leukodystrophy with a characteristic MRI pattern of brain stem involvement. AJNR Am J Neuroradiol. 2019;40(5):903-907. https://doi.org/10.3174/ajnr.A6051
Loddenkemper T, Grote K, Evers S, Oelerich M, Stögbauer F. Neurological manifestations of the oculodentodigital dysplasia syndrome. J Neurol. 2002;249(5):584-595. https://doi.org/10.1007/s004150200068
Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, et al. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138(Pt 2):284-292. https://doi.org/10.1093/brain/awu353
Ganos C, Münchau A, Holst B, Schlüter G, Gerloff C, Uyanik G. Teaching neuroimages: oculodentodigital dysplasia: hypomyelination and syndactyly. Neurology. 2012;79(16):e140. https://doi.org/10.1212/WNL.0b013e31826e9b51
Carvalho CMB, Bartnik M, Pehlivan D, Fang P, Shen J, Lupski JR. Evidence for disease penetrance relating to CNV size: Pelizaeus-Merzbacher disease and manifesting carriers with a familial 11 Mb duplication at Xq22. Clin Genet. 2012;81(6):532-541. https://doi.org/10.1111/j.1399-0004.2011.01716.x
Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta. 2012;1822(9):1430-1441. https://doi.org/10.1016/j.bbadis.2012.04.006
Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol. 1998;8(1):101-120. https://doi.org/10.1111/j.1750-3639.1998.tb00139.x
Régal L, S M, Goemans N, et al. Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol. 2010;68(2):259-263. https://doi.org/10.1002/ana.22035
Matsui S, Funahashi M, Honda A, Shimozawa N. Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene. Brain Dev. 2013;35(9):842-848. https://doi.org/10.1016/j.braindev.2012.10.017
Ebberink MS, Mooijer PAW, Gootjes J, Koster J, Wanders RJA, Waterham HR. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat. 2011;32(1):59-69. https://doi.org/10.1002/humu.21388
Krause C, Rosewich H, Thanos M, Gärtner J. Identification of novel mutations in PEX2, PEX6, PEX10, PEX12, and PEX13 in Zellweger spectrum patients. Hum Mutat. 2006;27(11):1157. https://doi.org/10.1002/humu.9462
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. https://doi.org/10.1038/gim.2015.30
Steenweg ME, Vanderver A, Blaser S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010;133(10):2971-2982. https://doi.org/10.1093/brain/awq257
Wolf NI, Vanderver A, van Spaendonk RML, et al. Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. Neurology. 2014;83(21):1898-1905. https://doi.org/10.1212/WNL.0000000000001002
Cayami FK, Bugiani M, Pouwels PJW, Bernard G, van der Knaap MS, Wolf NI. 4H leukodystrophy: lessons from 3T imaging. Neuropediatrics. 2018;49(2):112-117. https://doi.org/10.1055/s-0037-1608780
Gauquelin L, Cayami FK, Sztriha L, et al. Clinical spectrum of POLR3-related leukodystrophy caused by biallelic POLR1C pathogenic variants. Neurol Genet. 2019;5(6):e369. https://doi.org/10.1212/NXG.0000000000000369

Auteurs

Daniela Di Bella (D)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Stefania Magri (S)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Chiara Benzoni (C)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Laura Farina (L)

Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Neuroimaging Laboratory, IRCCS Fondazione Santa Lucia, Rome, Italy.

Carmelo Maccagnano (C)

Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Elisa Sarto (E)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Marco Moscatelli (M)

Unit of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Silvia Baratta (S)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Claudia Ciano (C)

Unit of Neurophysiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Sylvie H M J Piacentini (SHMJ)

Unit of Neuropsychology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Lara Draghi (L)

Unit of Neuropsychology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Elena Mauro (E)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Davide Pareyson (D)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Cinzia Gellera (C)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Franco Taroni (F)

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Ettore Salsano (E)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Neuroscience PhD Program, University of Milano-Bicocca, Monza, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH